Skip to main content
Erschienen in: Applied Health Economics and Health Policy 2/2011

01.03.2011 | Original Research Article

Impact of fibromyalgia severity on health economic costs

Results from a European cross-sectional study

verfasst von: Andreas Winkelmann, Serge Perrot, Ms Caroline Schaefer, Kellie Ryan, Arthi Chandran, Alesia Sadosky, Gergana Zlateva

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Fibromyalgia (FM) is a chronic disorder characterized by persistent and widespread pain, often accompanied with fatigue, sleep disturbance and other symptoms. FM affects a population mostly of a productive age and is thus associated with significant lost productivity and disability, in addition to healthcare costs for medications and physician office visits. While other studies have examined FM costs in Europe, few, if any, have examined cost by FM severity level.

Objective

The objective of this study was to examine health resource utilization (HRU) and costs associated with FM in routine clinical practice in France and Germany across disease severity levels.

Methods

A total of 299 patients with FM, previously diagnosed by a rheumatologist, were recruited from physician offices in France and Germany during routine visits. Subjects completed questions about their pain, health-related quality of life, treatment satisfaction, productivity and FM-related out-of-pocket expenses; site staff recorded clinical, treatment and HRU information for the previous 3 months based on a review of medical records. FM severity was defined using subjects’ Fibromyalgia Impact Questionnaire (FIQ) total scores. Annual costs from a societal perspective were calculated in h, year 2008 values, and included direct costs (e.g. physician office visits, medications, out-of-pocket expenses) and indirect costs (e.g. missed days of work and lost productivity). The mean annual costs were calculated based on 3-month data.

Results

Subjects were reported to have a mean (SD) of 2.9 (1.9) physician office visits in France and 4.9 (3.2) visits in Germany over the past 3 months, corresponding to an average of 11.6 and 19.6 visits a year, respectively. A total of 91% of subjects were receiving prescription medication for their FM. French subjects reported a lower use of anti-inflammatories (39% of subjects) and a higher use of other analgesics (59% of subjects) than German subjects (67% and 34%, respectively). Subjects in full- or part-time employment reported missing a mean (SD) of 2.7 (6.0) days of work due to FM in France and 2.1 (3.8) days in Germany over the last 4 weeks (corresponding to 32.4 and 25.2 days of work missed due to FM per year in France and Germany, respectively). In France, total costs were €7900 (direct €910, indirect €6990). In Germany, total costs were €7256 (direct €1765, indirect €5491). A trend of higher total costs was seen as FM severity increased; however, the results were significant (p = 0.003) only for Germany.

Conclusions

FM imposes a significant economic burden on society. Consistent with other studies, FM subjects were found to have substantial costs, over 75% of which were driven by indirect costs from lost productivity. These costs increased as FM severity increased, resulting in a more than 200% difference in cost between mild and severe FM. Overall FM costs were similar between France and Germany; although lost productivity accounted for a higher proportion of costs in France.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
Key elements of the ACR criteria are chronic widespread pain for at least 3 months and tenderness in at least 11 of 18 tender point sites, which is measured by applying approximately 4 kg of pressure at each of the 18 sites.
 
Literatur
1.
Zurück zum Zitat Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28PubMedCrossRef Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28PubMedCrossRef
2.
Zurück zum Zitat Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003; 17: 658–701 Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003; 17: 658–701
3.
Zurück zum Zitat Arnold LM, Hudson JI, Keck Jr PE, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006; 67: 1219–25PubMedCrossRef Arnold LM, Hudson JI, Keck Jr PE, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006; 67: 1219–25PubMedCrossRef
4.
Zurück zum Zitat Bigatti SM, Hernandez AM, Cronan TA, et al. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum 2008; 59(7): 961–7PubMedCrossRef Bigatti SM, Hernandez AM, Cronan TA, et al. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum 2008; 59(7): 961–7PubMedCrossRef
5.
Zurück zum Zitat White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008; 50: 13–24PubMedCrossRef White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008; 50: 13–24PubMedCrossRef
6.
Zurück zum Zitat Ablin J, Neumann L, Buskila D. Pathogenesis of fibromyalgia: a review. Joint Bone Spine 2008; 75(3): 273–9PubMedCrossRef Ablin J, Neumann L, Buskila D. Pathogenesis of fibromyalgia: a review. Joint Bone Spine 2008; 75(3): 273–9PubMedCrossRef
7.
Zurück zum Zitat Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33(2): 160–72PubMedCrossRef Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33(2): 160–72PubMedCrossRef
8.
Zurück zum Zitat Buckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. Glenview (IL): American Pain Society (APS), 2005. Clinical practice guideline no. 4 Buckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. Glenview (IL): American Pain Society (APS), 2005. Clinical practice guideline no. 4
9.
Zurück zum Zitat Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008 Apr; 67(4): 536–41PubMedCrossRef Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008 Apr; 67(4): 536–41PubMedCrossRef
10.
Zurück zum Zitat Häuser W, Arnold B, Eich W, et al. Management of fibromyalgia syndrome: an interdisciplinary evidence-based guideline. GMS German Medical Science 2008; 6: 1–11 Häuser W, Arnold B, Eich W, et al. Management of fibromyalgia syndrome: an interdisciplinary evidence-based guideline. GMS German Medical Science 2008; 6: 1–11
11.
Zurück zum Zitat Nazonov D, Soladov D, Le Lay K, et al. Prevalence of fibromyalgia: a large-scale European survey. Results in Russia [poster]. European League Against Rheumatism (EULAR) 9th Annual Congress; 2008 Jun 11–14; Paris Nazonov D, Soladov D, Le Lay K, et al. Prevalence of fibromyalgia: a large-scale European survey. Results in Russia [poster]. European League Against Rheumatism (EULAR) 9th Annual Congress; 2008 Jun 11–14; Paris
12.
Zurück zum Zitat Späth M, Le Lay K, Boussetta S, et al. Prevalence of fibromyalgia: a large-scale European survey. Results in Germany [poster]. EULAR 9th Annual Congress; 2008 Jun 11–14; Paris Späth M, Le Lay K, Boussetta S, et al. Prevalence of fibromyalgia: a large-scale European survey. Results in Germany [poster]. EULAR 9th Annual Congress; 2008 Jun 11–14; Paris
13.
Zurück zum Zitat Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005; 23 Suppl. 39: S154–62 Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005; 23 Suppl. 39: S154–62
14.
Zurück zum Zitat Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991; 18: 728–33PubMed Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991; 18: 728–33PubMed
15.
Zurück zum Zitat Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005; 64: 396–402PubMedCrossRef Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005; 64: 396–402PubMedCrossRef
16.
Zurück zum Zitat Hughes G, Martinez C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arth Rheum 2006; 54(1): 177–83CrossRef Hughes G, Martinez C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arth Rheum 2006; 54(1): 177–83CrossRef
17.
Zurück zum Zitat Berger A, Sadosky A, Dukes E, et al. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Op 2008; 24(9): 2489–99CrossRef Berger A, Sadosky A, Dukes E, et al. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Op 2008; 24(9): 2489–99CrossRef
18.
Zurück zum Zitat Annemans L, Le Lay K, Taieb C. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics 2009; 27(7): 547–59PubMedCrossRef Annemans L, Le Lay K, Taieb C. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics 2009; 27(7): 547–59PubMedCrossRef
19.
Zurück zum Zitat Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arth Rheum 2008; 58(3): 895–902CrossRef Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arth Rheum 2008; 58(3): 895–902CrossRef
20.
Zurück zum Zitat Sinclair JD, Starz TW, Turk DC. The Manual Tender Point Survey, 1997, Pittsburgh, PA: University of Pittsburgh Medical Center. Copyright 1997 by the University of Pittsburgh Medical Center, Center for Continuing Education in the Health Sciences. Instructions adapted from The Manual Tender Point Survey [online]. Available from URL: http://www.fmaware.org/site/News2?page=NewsArticle&id=6263 [Accessed 2007 May 16] Sinclair JD, Starz TW, Turk DC. The Manual Tender Point Survey, 1997, Pittsburgh, PA: University of Pittsburgh Medical Center. Copyright 1997 by the University of Pittsburgh Medical Center, Center for Continuing Education in the Health Sciences. Instructions adapted from The Manual Tender Point Survey [online]. Available from URL: http://​www.​fmaware.​org/​site/​News2?​page=​NewsArticle&​id=​6263 [Accessed 2007 May 16]
21.
Zurück zum Zitat Perrot S, Winkelmann A, Xu X, et al. How does fibromyalgia impact patients? Results from a European Cross-Sectional Study. EULAR 10th Annual Congress; 2009 Jun 10–13; Copenhagen Perrot S, Winkelmann A, Xu X, et al. How does fibromyalgia impact patients? Results from a European Cross-Sectional Study. EULAR 10th Annual Congress; 2009 Jun 10–13; Copenhagen
22.
Zurück zum Zitat Perrot S, Winkelmann A, Schaefer C, et al. Impact of fibromyalgia severity on quality of life and pain: results from a multinational cross-sectional survey. European Federation of Neurological Societies 13th Annual Congress; 2009 Sep 12–15; Florence Perrot S, Winkelmann A, Schaefer C, et al. Impact of fibromyalgia severity on quality of life and pain: results from a multinational cross-sectional survey. European Federation of Neurological Societies 13th Annual Congress; 2009 Sep 12–15; Florence
23.
Zurück zum Zitat Perrot S, Winkelmann A, Dukes E, et al. Characteristics of patients with fibromyalgia in France and Germany. Int J Clin Pract 2010 Jul; 64(8): 1100–8PubMedCrossRef Perrot S, Winkelmann A, Dukes E, et al. Characteristics of patients with fibromyalgia in France and Germany. Int J Clin Pract 2010 Jul; 64(8): 1100–8PubMedCrossRef
24.
Zurück zum Zitat Bennett RM, Bushmakin AG, Cappelleri JC, et al. Clinically important percentage change in the Fibromyalgia Impact Questionnaire. J Rheumatol 2009; 36(6): 1304–11PubMedCrossRef Bennett RM, Bushmakin AG, Cappelleri JC, et al. Clinically important percentage change in the Fibromyalgia Impact Questionnaire. J Rheumatol 2009; 36(6): 1304–11PubMedCrossRef
25.
Zurück zum Zitat Zelman D, Dukes E, Brandenburg N, et al. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain 2005; 115(1-2): 29–36PubMedCrossRef Zelman D, Dukes E, Brandenburg N, et al. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain 2005; 115(1-2): 29–36PubMedCrossRef
29.
Zurück zum Zitat University Clinic, Münster, Westphalia Wilhelms University Münster. German Diagnosis-Related Group Webgrouper 2008 [online]. Available from URL: http://drg.uni-muenster.de/ [Accessed 2008 Apr 1] University Clinic, Münster, Westphalia Wilhelms University Münster. German Diagnosis-Related Group Webgrouper 2008 [online]. Available from URL: http://​drg.​uni-muenster.​de/​ [Accessed 2008 Apr 1]
33.
Zurück zum Zitat Sicras-Mainar A, Rejas J, Navarro R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009; 11(2): R54PubMedCrossRef Sicras-Mainar A, Rejas J, Navarro R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009; 11(2): R54PubMedCrossRef
34.
Zurück zum Zitat Wolfe F, Anderson J, Harkness D, et al. Health status and disease severity in fibromyalgia. Arth Rheum 1997; 40(9): 1571–9CrossRef Wolfe F, Anderson J, Harkness D, et al. Health status and disease severity in fibromyalgia. Arth Rheum 1997; 40(9): 1571–9CrossRef
35.
Zurück zum Zitat Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003; 30(6): 1318–25PubMed Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003; 30(6): 1318–25PubMed
Metadaten
Titel
Impact of fibromyalgia severity on health economic costs
Results from a European cross-sectional study
verfasst von
Andreas Winkelmann
Serge Perrot
Ms Caroline Schaefer
Kellie Ryan
Arthi Chandran
Alesia Sadosky
Gergana Zlateva
Publikationsdatum
01.03.2011
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 2/2011
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.2165/11535250-000000000-00000

Weitere Artikel der Ausgabe 2/2011

Applied Health Economics and Health Policy 2/2011 Zur Ausgabe